BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

BioLife is a publicly traded business that makes products used by biotech firms to keep living cells alive and healthy while they’re stored, shipped, frozen or thawed for medical therapies. Waltham, Mass.-based Repligen makes tools and other materials used to manufacture vaccines, antibodies and other biological therapies. Both companies launched in the 1980s.

Cell and gene therapies are advanced treatments that use living cells or genetic material to treat disease at the molecular level. Cell therapies replace or repair damaged tissue with healthy cells, while gene therapies add, fix or modify DNA to correct the underlying cause of a condition.

“Over the past several years, we have successfully repositioned BioLife around our market-leading biopreservation media franchise, while strengthening our financial profile and establishing a durable foundation for profitable growth,” said Roderick de Greef, CEO of BioLife, in a statement.

BioLife shareholders will get $11.25 in cash plus 0.1442 shares of Repligen stock for every share of BioLife they own—bringing the total deal value to $31 per share.

The deal is expected to close in the fourth quarter, pending BioLife stockholder approval and regulatory clearance.